Genmab A/S shares surged the most in more than six years after its experimental ovarian cancer treatment exceeded analyst expectations in a late-stage trial, boosting confidence in the Danish drugmaker’s pipeline.
CryptoAlerta — análise de criptomoedas e mercado em tempo real